Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04511845 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Chugai Pharmaceutical.
- Active
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 15
- Study locations
NCT04511845: Active Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Chugai Pharmaceutical.
NCT04511845 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors that is active but no longer recruiting, run by Chugai Pharmaceutical. The registered enrollment target is 113 participants, below the 276-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (59% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04511845, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors, is active but no longer recruiting, sponsored by Chugai Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 15
- Study locations
Study Summary
Phase I, open-label, multi-center study
Primary Outcome
Incidence and nature of DLTs
Conditions Studied
Interventions
- DRUG SPYK04
Study Locations (15)
Texas
- MD Anderson Cancer Center - Houston
- Texas Oncology - Tyler
Virginia
- University of Virginia - Charlottesville
- Virginia Cancer Specialists - Fairfax
Tokyo
- National Cancer Center Hospital - Chuo Ku
- Cancer Institute Hospital of Japanese Foundation for Cancer Research - Koto-Ku
Other
- National Hospital Organization Kyushu Cancer Center - Fukuoka
- Osaka Prefectural Hospital Organization Osaka International Cancer Center - Osaka
Arizona
- Arizona Oncology - Tucson
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Minnesota
- Minnesota Oncology - Minneapolis
Rhode Island
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2020-09-10 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
What the registry record for NCT04511845 still lists
NCT04511845 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 276-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SPYK04 is the first listed.
NCT04511845 lists 15 locations in 11 states (Texas, Virginia, Tokyo).
Frequently Asked Questions
What is clinical trial NCT04511845 about?
NCT04511845 is a clinical study titled "A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).". Phase I, open-label, multi-center study
What is the current status of trial NCT04511845?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2020-09-10. Estimated completion is 2026-09-30.
What conditions does trial NCT04511845 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT04511845?
The interventions under investigation include: SPYK04 (DRUG).
Who is sponsoring clinical trial NCT04511845?
This trial is sponsored by Chugai Pharmaceutical, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04511845 being conducted?
This trial has 15 study locations across Arizona, Colorado, Minnesota, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT05799248 · 113 participants · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI